

# Serum TNF-A Concentrations In Type Two Diabetes Mellitus

Abbas Jameel Al-Sarray<sup>1</sup> and Intisar Hussein Ahmed<sup>1</sup>

<sup>1</sup>Department of Biology, College of Education for pure sciences, University of Wasit, Iraq

---

## Abstract

Diabetes is one of the most common metabolic diseases, and its incidence continues to increase in many parts of the world. It is estimated that more than 90% of diabetes is type 2 diabetes mellitus (T2DM), which occurs for two main reasons: a lack of insulin production by  $\beta$ -cells of the pancreas, as well as peripheral insulin resistance (IR) in many organs such as the liver, skeletal muscles, and adipose tissues. It can be considered that pro-inflammatory cytokines are one of the most important variables that lead to T2DM and also contribute to the development of insulin resistance. Tumor necrosis factor-alpha (TNF- $\alpha$ ) is the most important pro-inflammatory mediators, as it causes inflammation in various parts of the body.

TNF- $\alpha$  concentrations in sera were measured by enzyme-linked immunosorbent assay technique (ELISA) using Human tumor necrosis factor-alpha (TNF- $\alpha$ ) ELISA Kit (Elabscience Company /china).

Serum TNF- $\alpha$  concentrations displayed a significant difference in T2DM patients when compared with the control group (Diabetic patients  $30.36 \pm 14.51$  compared with control  $23.30 \pm 7.030$ , P-value = 0.0149, T-test = 2.489). TNF- $\alpha$  concentrations of males with diabetic patients displayed significant difference when compared with controls ( $31.83 \pm 13.27$  versus  $22.41 \pm 6.32$ , P-value = 0.0438, T-test = 2.751). However, the TNF- $\alpha$  concentrations of females of diabetic patients displayed non-significant difference when compared with controls ( $28.87 \pm 7.7$  versus  $24.19 \pm 7.79$ , P-value = 0.4377, T-test = 1.069).

We conclude that there may be a correlation between high levels of TNF- $\alpha$  and type 2 diabetes mellitus (T2DM).

**Keywords:** TNF- $\alpha$ , T2DM, ELISA

---

## 1. Introduction

Diabetes is one of the most common metabolic diseases, and its incidence continues to increase in many parts of the world (Zochodne, 2014). It is estimated that more than 90% of diabetes is type 2 diabetes mellitus (T2DM), which occurs for two main reasons: a lack of insulin production by  $\beta$ -cells of the pancreas, as well as peripheral insulin resistance (IR) in many organs such as the liver, skeletal muscles, and adipose tissues (Galicia-Garcia et al., 2020). There is ample evidence that the development of T2DM is the result of a combination of environmental and genetic variables (Goldstein, 2003; Z. Li et al., 2020). It can be

considered that pro-inflammatory cytokines are one of the most important variables that lead to T2DM and also contribute to the development of insulin resistance (Akash et al., 2013; Donath & Shoelson, 2011). Tumor necrosis factor-alpha (TNF- $\alpha$ ) is the most important pro-inflammatory mediators, as it causes inflammation in various parts of the body (Donath & Shoelson, 2011). TNF- $\alpha$  is thought to be one of the most important pro-inflammatory cytokines, having polymorphic effects and varying amounts from person to person. It is important in the host's defense against infections and also plays a role in autoimmune disorders (Sandhya et al., 2013).

In patients with T2DM and insulin resistance, TNF- $\alpha$  levels are unusually high, indicating that this cytokine plays an important role in the development of insulin resistance and pathogenesis of T2DM (Chen et al., 2015). As a result the relationship among TNF- $\alpha$  and T2DM seems to have become a subject of diabetic research (M. Y. Shiau et al., 2003). The number of cytokines that have been studied for their association with T2DM is very large, and TNF- $\alpha$  is one of these cytokines that took a large part of this kind of study. Because of the different results of many studies, this study aims to evaluate the levels of TNF- $\alpha$  in the sera of patients with T2DM by means of Enzyme - linked immunosorbent assay (ELISA).

## 2. Materials and Methods

This study included (50) patients with T2DM ( 25 males, 25 females ) whose ages ranged from 40 to 80 years, and (30) apparently healthy individuals (controls) subjects (15 males and 15 females) whose ages ranged from 37 to 65 years. They were chosen from different hospitals in Wasit governorate which include: AL-Zahra, a hospital, AL-Karamah hospital, and private clinics from different regions in Wasit governorate. The glycemc status of patients with diabetes and controls was used to differentiate them. Verbal consent was taken from all participants. Age, sex, weight, BMI, smoking, medications, and medical or family history of diabetes were all measured using standardized questionnaires.

Five milliliters of blood were collected from all participants and placed in a tube without anticoagulant and placed in a centrifuge at a speed of 2000 rpm for 10 minutes. After that, the serum was withdrawn into an eppendorff tube 2ml and preserved after being labeled with deep freezing until further processed.

TNF- $\alpha$  concentrations in sera were measured by enzyme-linked immunosorbent assay technique (ELISA) using Human tumor necrosis factor-alpha (TNF- $\alpha$ ) ELISA Kit (Elabscience Company/china).

## 3. Results


The results are shown in Table 1 and Figure 1. Serum TNF- $\alpha$  concentrations displayed a significant difference in T2DM patients when compared with the control group (Diabetic patients  $30.36 \pm 14.51$  compared with control  $23.30 \pm 7.030$ , P-value = 0.0149, T-test = 2.489).

**Table 1: Concentration of serum TNF- $\alpha$  in diabetic and control groups**

Parameters Groups	TNF Pg/ml Mean + SD
Control	23.30 $\pm$ 7.030
Diabetic Patients	30.36 $\pm$ 14.51
P-value	0.0149 *
T-test	2.489

\*

significant at p-value  $\leq$  0.05



**Figure 1: Concentration of serum TNF- $\alpha$  in diabetic and control groups.**

The assessment of circulating levels of TNF- $\alpha$  on the basis of gender (males and females) of investigated groups are described in Table 2 and Figure 2. TNF- $\alpha$  concentrations of males with diabetic patients displayed significant difference when compared with controls (31.83  $\pm$  13.27 versus 22.41  $\pm$  6.32, P-value = 0.0438, T-test = 2.751). However, the TNF- $\alpha$  concentrations of females of diabetic patients displayed non-significant difference when compared with controls (28.87  $\pm$  7.79 versus 24.19  $\pm$  7.79, P-value = 0.4377, T-test = 1.069).

**Table 2: Concentration of serum TNF- $\alpha$  on the basis of gender (males and females) in diabetic and control groups.**

Parameters	TNF Pg/ml Mean + SD

Groups	male	Female	P-value	T-test
Control	22.41 ± 6.32	24.19 ± 7.79	0.9059	0.69 NS
Diabetic Patients	31.83 ± 13.27	28.87 ± 77	0.6394	0.7183 NS
P-value	0.0438	0.4377	----	----
T-test	2.751 *	1.069 NS	----	----

NS=Non-significant, \* significant at p value ≤ 0.05.




Figure 2: Concentration of serum TNF-α on the basis of gender (males and females) in diabetic and control groups.

#### 4. Discussion

The current study revealed a significant difference of TNF-α levels when compared patients with T2DM to controls (Diabetic patients 30.36 ± 14.51 compared with control 23.30 ± 7.030, P-value = 0.0149, T-test = 2.489). These results are in agreement with Abd-Elbaky and others on the residents of Egyptian population (Abd-Elbaky & M Abo-El Matty, 2016). Clausell et al., 1999 displayed that the TNF-α levels are elevated in diabetic patients. But these levels in another study in the blood of diabetic patients demonstrated decreased values (M.-Y. Shiao et al., 2003). Lu et al., 2011 also found the levels of TNF-α concentration was 1.92 in the patients of T2DM. Navarro et al. found the concentrations of this cytokine was 0.27 in the patients group (Navarro et al., 2008). These findings are disagreed with our results.

Inflammation can be considered as an important characteristic of T2DM with high elevated levels of pro-inflammatory cytokines such as IL-1, IL-6, and TNF- $\alpha$  (Thamer et al., 2021). Considering TNF- $\alpha$  can disrupt insulin signaling pathways and destroy  $\beta$ -cells, increased production of TNF- $\alpha$  may play a key role in the development of T2DM (Nishimura et al., 2003).

Based on our study, TNF- $\alpha$  concentrations of males with diabetic patients displayed significant difference when compared with controls ( $31.83 \pm 13.27$  versus  $22.41 \pm 6.32$ , P-value = 0.0438, T-test = 2.751). Female diabetic patients, on the other hand, had non-significant differences in TNF- $\alpha$  concentrations when compared to controls ( $28.87 \pm 7.79$  versus  $24.19 \pm 7.79$ , P-value = 0.4377, T-test = 1.069). Hellmich et al., 2000 discovered that sera from T2DM patients had considerably higher TNF- $\alpha$  than sera from normoglycemic controls. TNF- $\alpha$  has pro-inflammatory properties, although it may also have other effects (Jamil et al., 2017; H. Li et al., 2003). TNF- $\alpha$  is primarily involved in regulatory immune cells. TNF- $\alpha$  may hasten the release and synthesis of inflammatory cytokines and contribute to the advancement of T2DM (Fritzenwanger et al., 2009).

There were substantial differences in blood TNF- $\alpha$  levels between patients and control groups in various investigations (Abd-Elbaky & M Abo-El Matty, 2016; Hellmich et al., 2000; Ishii et al., 2000). These results indicate that TNF- $\alpha$  serum levels may have some pathogenic roles in T2DM.

## **5. Conclusion**

There may be a correlation between high levels of TNF- $\alpha$  and type 2 diabetes mellitus (T2DM).

## References

- Abd-Elbaky, A. E., & M Abo-El Matty, D. (2016). Adiponectin (+276 G/T), Tumor Necrosis Factor-alpha (-308 G/A) and Interleukin-6 (-174 C/G) Genes Polymorphisms in Egyptian Type 2 Diabetic Patients. *Journal of Diabetes & Metabolism*, 07(05), 1–10. <https://doi.org/10.4172/2155-6156.1000673>
- Akash, M. S. H., Rehman, K., & Chen, S. (2013). Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. *Journal of Cellular Biochemistry*, 114(3), 525–531. <https://doi.org/https://doi.org/10.1002/jcb.24402>
- Chen, L., Chen, R., Wang, H., & Liang, F. (2015). Mechanisms Linking Inflammation to Insulin Resistance. In *International Journal of Endocrinology* (Vol. 2015). <https://doi.org/10.1155/2015/508409>
- Clausell, N., Kalil, P., Biolo, A., Molossi, S., & Azevedo, M. (1999). Increased expression of tumor necrosis factor- $\alpha$  in diabetic macrovasculopathy. *Cardiovascular Pathology*, 8(3), 145–151. [https://doi.org/10.1016/S1054-8807\(98\)00033-7](https://doi.org/10.1016/S1054-8807(98)00033-7)
- Donath, M. Y., & Shoelson, S. E. (2011). Type 2 diabetes as an inflammatory disease. *Nature Reviews Immunology*, 11(2), 98–107. <https://doi.org/10.1038/nri2925>
- Fritzenwanger, M., Meusel, K., Jung, C., Franz, M., Wang, Z., Foerster, M., & Figulla, H. R. (2009). Cardiotrophin-1 induces tumor necrosis factor synthesis in human peripheral blood mononuclear cells. *Mediators of Inflammation*, 2009. <https://doi.org/10.1155/2009/489802>
- Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. In *International Journal of Molecular Sciences* (Vol. 21, Issue 17, pp. 1–34). <https://doi.org/10.3390/ijms21176275>
- Goldstein, B. J. (2003). Insulin resistance: From benign to type 2 diabetes mellitus. *Reviews in Cardiovascular Medicine*, 4(SUPPL. 6), 3–10.
- Hellmich, B., Schellner, M., Schatz, H., & Pfeiffer, A. (2000). Activation of transforming growth factor- $\beta$ 1 in diabetic kidney disease. *Metabolism*, 49(3), 353–359. [https://doi.org/https://doi.org/10.1016/S0026-0495\(00\)90264-6](https://doi.org/https://doi.org/10.1016/S0026-0495(00)90264-6)
- Ishii, T., Hirose, H., Saito, I., Nishikai, K., Maruyama, H., & Saruta, T. (2000). Tumor necrosis factor alpha gene G-308A polymorphism, insulin resistance, and fasting plasma glucose in young, older, and diabetic Japanese men. *Metabolism: Clinical and Experimental*, 49(12), 1616–1618. <https://doi.org/10.1053/meta.2000.18560>
- Jamil, K., Jayaraman, A., Ahmad, J., Joshi, S., & Yerra, S. K. (2017). TNF-alpha -308G/A and -238G/A polymorphisms and its protein network associated with type 2 diabetes mellitus. *Saudi Journal of Biological Sciences*, 24(6), 1195–1203. <https://doi.org/10.1016/j.sjbs.2016.05.012>
- Li, H., Groop, L., Nilsson, A., Weng, J., & Tuomi, T. (2003). A combination of human leukocyte antigen DQB1\*02 and the tumor necrosis factor  $\alpha$  promoter G308A polymorphism predisposes to an insulin-deficient phenotype in patients with type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, 88(6), 2767–2774. <https://doi.org/10.1210/jc.2002-020506>

- Li, Z., Ye, C. Y., Zhao, T. Y., Zhao, T. Y., & Yang, L. (2020). Model of genetic and environmental factors associated with type 2 diabetes mellitus in a Chinese Han population. *BMC Public Health*, 20(1). <https://doi.org/10.1186/s12889-020-09130-5>
- Lu, J., Randell, E., Han, Y., Adeli, K., Krahn, J., & Meng, Q. H. (2011). Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. *Clinical Biochemistry*, 44(4), 307–311. <https://doi.org/https://doi.org/10.1016/j.clinbiochem.2010.11.004>
- Navarro, J. F., Mora, C., Gómez, M., Muros, M., López-Aguilar, C., & García, J. (2008). Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor- $\alpha$  and interleukin-6 in type 2 diabetic patients. *Nephrology Dialysis Transplantation*, 23(3), 919–926. <https://doi.org/10.1093/ndt/gfm674>
- Nishimura, M., Obayashi, H., Mizuta, I., Hara, H., Adachi, T., Ohta, M., Tegoshi, H., Fukui, M., Hasegawa, G., Shigeta, H., Kitagawa, Y., Nakano, K., Kaji, R., & Nakamura, N. (2003). TNF, TNF receptor type 1, and allograft inflammatory factor-1 gene polymorphisms in Japanese patients with type 1 diabetes. In *Human Immunology* (Vol. 64, Issue 2, pp. 302–309). [https://doi.org/10.1016/S0198-8859\(02\)00799-1](https://doi.org/10.1016/S0198-8859(02)00799-1)
- Sandhya, P., Danda, S., Danda, D., Lonarkar, S., Luke, S. S., Sinha, S., & Joseph, G. (2013). Tumour necrosis factor (TNF)- $\alpha$ -308 gene polymorphism in Indian patients with Takayasu's arteritis - a pilot study. *The Indian Journal of Medical Research*, 137(4), 749–752.
- Shiau, M.-Y., Wu, C.-Y., Huang, C.-N., Hu, S.-W., Lin, S.-J., & Chang, Y.-H. (2003). TNF- $\alpha$  polymorphisms and type 2 diabetes mellitus in Taiwanese patients. *Tissue Antigens*, 61(5), 393–397. <https://doi.org/https://doi.org/10.1034/j.1399-0039.2003.00059.x>
- Shiau, M. Y., Wu, C. Y., Huang, C. N., Hu, S. W., Lin, S. J., & Chang, Y. H. (2003). TNF- $\alpha$  polymorphisms and type 2 diabetes mellitus in Taiwanese patients. *Tissue Antigens*, 61(5), 393–397. <https://doi.org/10.1034/j.1399-0039.2003.00059.x>
- Salim Oudah Mezan, Salih Meri Al Absi, Abdullah Hasan Jabbar et al., Synthesis and characterization of enhanced silica nanoparticle (SiO<sub>2</sub>) prepared from rice husk ash immobilized of 3-(chloropropyl) triethoxysilane, *Materials Today: Proceedings*, <https://doi.org/10.1016/j.matpr.2020.12.564>
- Zochodne, D. W. (2014). Diabetes Mellitus. In M. J. Aminoff & R. B. Daroff (Eds.), *Encyclopedia of the Neurological Sciences* (Second Edition) (Second Ed, pp. 992–994). Academic Press. <https://doi.org/https://doi.org/10.1016/B978-0-12-385157-4.00080-4>